Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus PD-1 antibody and reduced-dose FLOT versus PD-1 antibody and reduced-dose FLOT for neoadjuvant treatment of locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300076276Phase 3Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Oct 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib, docetaxel, oxaliplatin, folinic acid and fluorouracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoints: Pathological complete response rate and Overall response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Rivoceranibdocetaxeloxaliplatinfolinic acidfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300076276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076276.